🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Becton, Dickinson and Company BDX SPXR3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.bd.com
Company Profile ↓
$184.74
+22.86% 1Y
Mkt Cap$50.90B
P/E32.02
P/B1.99
Div. Yield2.37%
52W High$192.00
52W Low$136.09
Book Value$88.85
EPS (TTM)$5.77

Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Why Investors Should Care

Healthy Margins

Operating margin of 15.1% supports profitability.

Dividend Income

Offers a dividend yield of 2.37%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Sep 2025 Revenue of $21.84B (+8.2% YoY); net profit $1.68B.
  • Trailing 12 Months Year-on-year growth — revenue -9.5%, earnings -31.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.0%, profit CAGR -1.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.99%
1 Year:-9.50%

Compounded Profit Growth

5 Years:-1.93%
1 Year:-31.40%

Stock Price Performance

1 Year:+22.86%
6 Months:+12.03%
3 Months:+23.08%
1 Month:+4.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$136.09 $192.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.51 · Neutral
Price Performance
1M+4.33%
3M+23.08%
6M+12.03%
1Y+22.86%
Valuation vs Sector

P/E of 32.02 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -1.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
32.02
Industry PE
25.17
Forward P/E
13.86
PEG Ratio
1.11
Book Value
$88.85
Price to Book
1.99
P/S
2.17
EV/EBITDA
10.14
Dividend Yield
2.37%

Growth (CAGR)

Revenue 5Y
4.99%
Profit 5Y
-1.93%
Revenue (YoY)
-9.50%
Earnings (YoY)
-31.40%

Profitability & Returns

ROCE
6.35%
ROE
6.61%
ROA
4.66%
Profit Margin
4.19%
Op Margin
15.09%
Gross Margin
48.43%
EPS (Latest Qtr)
$1.37
EPS (TTM)
$5.77

Balance Sheet & Liquidity

Debt/Equity
0.69
Quick Ratio
0.33
Current Ratio
0.86
Debt
$16.81B
Total Assets
$50.73B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.43%
Chg in Prom Hold
0.01%
FII / Inst Holding
99.64%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
$50.90B
Total Revenue (TTM)
$22.48B
EBITDA
$6.39B
Free Cash Flow
$4.62B
Operating Cash Flow
$3.26B
Shares Outstanding
275.54M
Gross Margin
48.43%
Payout Ratio
72.49%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BDX Becton, Dickinson and Company SPXR3KPHARMA 184.74 32.02 $50.90B 2.37% 6.35% 6.61% 4.99% -1.93%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----2.92B2.97B3.04B3.17B3.08B4.22B4.28B4.40B4.16B4.20B4.35B4.58B4.22B4.25B3.85B4.78B5.32B4.91B4.61B4.72B4.75B4.64B4.59B4.82B4.88B4.71B5.04B4.99B-4.48B5.51B5.89B5.25B4.71B4.98B
Cost of Revenue ----------------------------------2.62B2.88B3.09B2.84B2.56B-
Gross Profit 1.43B1.41B1.48B1.55B1.55B1.45B1.43B1.50B1.55B1.55B1.61B2.02B2.09B1.97B1.97B2.07B2.27B1.98B1.73B1.66B2.21B-------------1.86B2.63B2.80B2.41B2.15B-
Operating Expenses ----------------------------------1.38B1.66B1.97B1.75B1.53B-
Operating Income -352.00M466.00M516.00M-811.00M446.00M-223.00M-235.00M186.00M512.00M-888.00M136.00M626.00M-501.00M370.00M358.00M-1.24B434.00M492.00M692.00M564.00M537.00M585.00M628.00M549.00M439.00M734.00M602.00M-477.00M979.00M826.00M662.00M626.00M663.00M
EBITDA ----------------------------------875.00M1.56B1.29B1.16B708.00M-
Interest Expense ----------------------------------150.00M152.00M155.00M153.00M149.00M-
Pretax Income ----------------------------------201.00M703.00M510.00M393.00M39.00M-
Tax Provision ----------------------------------43.00M129.00M17.00M11.00M76.00M-
Net Income 181.00M229.00M338.00M390.00M19.00M562.00M344.00M-132.00M327.00M-136.00M-12.00M594.00M-135.00M599.00M20.00M451.00M163.00M278.00M183.00M286.00M128.00M1.00B299.00M525.00M677.00M454.00M360.00M509.00M460.00M407.00M281.00M537.00M487.00M-308.00M574.00M493.00M382.00M-311.00M377.00M
Diluted EPS 0.841.061.561.800.092.581.58-0.751.24-0.76-0.192.03-0.642.05-0.071.510.450.870.530.970.363.350.941.722.281.501.181.701.531.360.961.851.681.041.072.00-1.34-1.111.37
R&D Expense -187.00M182.00M207.00M-182.00M187.00M186.00M-191.00M259.00M277.00M-258.00M252.00M282.00M-270.00M264.00M262.00M-291.00M317.00M330.00M314.00M327.00M315.00M313.00M337.00M306.00M290.00M299.00M299.00M343.00M232.00M297.00M-306.00M249.00M258.00M

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue 6.28B6.90B6.99B7.12B7.58B7.71B8.05B8.45B10.28B12.48B12.09B15.98B17.29B16.07B-18.87B19.37B20.18B21.84B
Cost of Revenue ---------------10.39B11.20B11.05B11.91B
Gross Profit -------4.30B4.70B5.99B5.94B7.27B8.29B7.58B-8.48B8.17B9.12B9.93B
Operating Expenses ---------------6.00B5.75B6.27B6.94B
Operating Income 1.18B1.49B1.59B1.58B1.67B1.56B1.25B1.61B1.07B1.43B1.52B1.51B1.76B912.00M-2.48B2.42B2.86B2.99B
EBITDA ---------------4.41B4.40B4.82B4.96B
Interest Expense ---------------398.00M452.00M528.00M613.00M
Pretax Income ---------------1.78B1.66B2.00B1.88B
Tax Provision ---------------148.00M132.00M300.00M203.00M
Net Income 890.03M1.13B1.23B--1.17B1.29B1.19B695.00M976.00M1.10B311.00M1.23B874.00M-1.78B1.48B1.71B1.68B
Diluted EPS 3.494.464.995.495.625.596.495.993.354.494.600.603.942.71-5.884.945.935.82
R&D Expense --404.57M422.77M470.00M472.00M494.00M550.00M632.00M828.00M770.00M1.00B1.06B1.04B1.28B1.26B1.24B1.19B1.26B

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2006Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets --7.91B9.30B9.65B10.43B11.36B12.15B12.38B26.48B25.59B37.73B53.90B51.77B54.01B53.87B52.93B52.78B57.29B55.33B
Total Equity --4.94B5.14B5.43B4.83B4.14B5.04B5.05B7.16B7.63B12.95B20.99B21.08B23.77B23.68B25.28B25.80B25.89B25.39B
Cash & Equivalents 1.00B511.48M830.48M1.39B1.22B1.18B1.67B1.89B1.86B1.42B1.54B14.18B1.14B536.00M2.83B2.28B1.01B1.42B1.72B641.00M
Long Term Debt ---1.49B1.50B2.48B3.76B3.76B3.77B11.37B10.55B18.67B18.89B18.08B17.22B17.11B13.89B14.74B17.94B17.62B
Current Liabilities --1.42B1.78B1.67B1.82B1.98B2.13B2.23B4.38B4.40B3.34B7.22B5.66B5.84B6.63B7.81B6.64B8.96B8.31B

Cash Flows (Annual)

Figures in USD.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow -------1.75B1.73B2.56B2.55B2.87B3.33B3.54B4.65B----
Investing Cash Flow --------948.00M-8.32B-669.00M-883.00M-15.73B-741.00M-1.23B-1.88B--716.00M-5.51B-818.00M
Financing Cash Flow --------807.00M6.19B-1.76B10.98B-58.00M-3.22B22.00M-3.31B--1.96B2.09B-3.62B
Capital Expenditure -556.29M-595.81M-585.20M-530.97M-509.00M-487.00M-522.00M-592.00M-596.00M-693.00M-727.00M-895.00M-957.00M-769.00M-1.19B-973.00M-874.00M-725.00M-760.00M
Free Cash Flow -------1.15B1.13B1.87B1.82B1.97B2.37B2.77B3.45B----
Share Buybacks 450.12M450.00M550.01M750.00M1.50B1.50B450.00M400.00M00220.00M0001.75B500.00M0500.00M1.00B

Ratios (Annual)

Figures in %.

Metric Sep 2007Sep 2008Sep 2009Sep 2010Sep 2011Sep 2012Sep 2013Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % -------50.9%45.7%48.0%49.1%45.5%47.9%47.1%-44.9%42.2%45.2%45.4%
Operating Margin % 18.9%21.6%22.8%22.2%22.0%20.2%15.6%19.0%10.4%11.5%12.6%9.4%10.2%5.7%-13.1%12.5%14.2%13.7%
Net Margin % 14.2%16.3%17.6%--15.2%16.1%14.0%6.8%7.8%9.1%1.9%7.1%5.4%-9.4%7.7%8.4%7.7%
ROE % -22.8%23.9%--28.3%25.6%23.5%9.7%12.8%8.5%1.5%5.8%3.7%-7.0%5.8%6.6%6.6%
ROCE % -22.9%21.1%19.8%19.4%16.6%12.5%15.8%4.9%6.7%4.4%3.2%3.8%1.9%-5.5%5.3%5.9%6.4%

Shareholding Pattern

Insiders
0.43%
Institutions
99.64%
Public Float
100.07%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.93% 24.59M $4.66B
2 Vanguard Capital Management LLC 6.53% 17.99M $3.41B
3 State Street Corporation 5.44% 15.00M $2.84B
4 Vanguard Portfolio Management LLC 5.43% 14.97M $2.84B
5 First Eagle Investment Management, LLC 5.01% 13.82M $2.62B
6 Invesco Ltd. 3.23% 8.90M $1.69B
7 Massachusetts Financial Services Co. 3.14% 8.65M $1.64B
8 Geode Capital Management, LLC 2.95% 8.14M $1.54B
9 Franklin Resources, Inc. 2.54% 7.01M $1.33B
10 Wellington Management Group, LLP 2.31% 6.36M $1.20B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BDX

Google News Fri, 21 Aug 2026

Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQdmJDcG1Ka2Jqdk5EZnFiQjU2S2Q4SmpERW5iSl9KanQ2VnJOSk9ycE5xWnhjZk1iUnljM0Y5aGY1ckFfLVNMMVA0eXllWVB1VVJCMGFGbmJGNTFQdFJBQWFpMnNZNjFHWTZESElMS2hUQldIaVBCV0ZCT3RTaFBzMW5rS1R3cHNmNmczcX…

Google News Fri, 04 Sep 2026

How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks? - Barchart.com

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNb0tMSVgtWU1kRVAzdE0yQjN0S2t0LVdNSVhWQ0g3S0hiYVZUWE93SHVIRy1NcUtHY0xZOFVaM0Y1ZTBNU0RleEFWakhkRW9BeUVyNTBfNkVTcmlLd05LTi1oZmNzVTZvX1Jpa2YzOF80S2Qwajg0NlZXR0V3SHNkM0l5VFdsTzJlTnJGTE…

Google News hu, 03 Sep 2026

Becton Dickinson (NYSE: BDX) CFO reports 190-share tax withholding - Stock Titan

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNVG9weDNaSERRV0tkM2FFalFlWHJEa1dGN0xOdk9JaXE0ZGxES0cwMVBXNWd6ZVFrdjViOGgtZW5ZeVNiN2VKVU9IbmxuSExXUFhlRDJGeU5UUk9Ic0paRjdIWXd4cm9PLXQ0Sk1XM1ExTFhZdGNYWjV2XzI0TmRnX3NVYkk5Mk45dlloeG…

Google News Sun, 09 Aug 2026

Becton Dickinson (BDX) Stock Still Looks Cheap After Its 19% Run - simplywall.st

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNSnJLa2pWNXFZbF9GTmd1aWtJaTBTalluN0FaM3BUMFJ4RmVXdnFpQ0RzUG9zczg5TUM5am81V3BPWUxvYW9MRlBFbGRkenFrRUd0LW9vb1VVTmYtRWtHd2FmdE4zU0FRaWtacVRxNnQycDhpLTktZFBhV0ExRzJRQk5rU2xteS11aGw3Mj…

Google News Mon, 31 Aug 2026

Here's Why You Should Retain BDX Stock in Your Portfolio Now - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQLVpJbHc3UlVKaFZpa2ZmT3N4NEJTZGV0WndicHZaaW1abDhJZDI5ZzRqY05FTHdVTDFpNENUTWs1WE04NjlRdkJ3aEdzT0ZlaGR6RWZvQnVkeXVTckF0ZWlDR3hqQXVEMURMVXNZbFB3LVg5a2d3T08tQmpPYUZzRTZ2VTgtaEpyX2tESH…

Google News Sat, 29 Aug 2026

BECTON DICKINSON AND CO (BDX) Stock Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE8zY01maUlzRGxneEpMNmVIYUo0Y2FFYTNaU3VBalZHeERuUU01UjAwVHVNbzJtWWl2c1Q1cVlUSG9yMHI3eDRsU0k1ZV9GWHlaSEhONmtvRG5TRm9Db3NMb3Y3VQ?oc=5" target="_blank">BECTON DICKINSON AND CO (BDX) Sto…

BDX — Frequently Asked Questions

What is the current share price of Becton, Dickinson and Company (BDX)?

As of 2026-09-07 16:24 PDT, Becton, Dickinson and Company (BDX) trades at $184.74 on NYSE. Its 52-week range is $136.09 to $192.00.

What is the market capitalisation of BDX?

Becton, Dickinson and Company (BDX) has a market capitalisation of $50.90B on NYSE.

What is the P/E ratio of BDX?

BDX trades at a trailing price-to-earnings (P/E) ratio of 32.02. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.99.

Does BDX pay a dividend?

Becton, Dickinson and Company (BDX) currently offers a dividend yield of 2.37%.

What is the return on equity (ROE) of BDX?

BDX has a return on equity (ROE) of 6.61%. Its return on capital employed (ROCE) is 6.35%.

Is BDX a good stock to buy?

This page provides a data-driven analysis of Becton, Dickinson and Company (BDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space